8-K: TOMI Reports 2025 Results, Eyes Global Growth Amid Revenue Dip

TOMI Environmental Solutions, Inc. announced its full-year 2025 financial results, reporting a decrease in net sales but highlighting strong gross margins, global expansion, and a robust future pipeline.

Summary

• Net sales for the year ended December 31, 2025, were $5,636,000, a decrease from $7,739,000 in 2024.
• Gross profit margin remained healthy at approximately 55%.
• Operating loss improved to ($3,854,000) in 2025 from ($4,105,000) in 2024.
• Net loss improved to $(3,749,000), or ($0.19) per basic and diluted share, compared to $(4,477,000), or ($0.22) per share, in 2024.
• International revenue grew to approximately 29% of total revenue in 2025, up from 21% in the prior year.
• Total operating expenses were reduced by approximately 10% in 2025.
• Sales backlog grew during 2025 to approximately $1.8 million.
• Cash and cash equivalents were $88,000 as of December 31, 2025, with working capital of $1.0 million.
• The accumulated deficit as of December 31, 2025, was $58.1 million.
• The company completed a $535,000 convertible note financing in 2025 and entered into an Equity Line of Credit (ELOC) for up to $20,000,000 in November 2025, with a first draw of $94,130 in February 2026.
• The total opportunity book for integration projects is $16 million, and the entire SteraMist iHP opportunity book is currently at $20 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While current year revenue declined and the company remains unprofitable, the strong gross margins, operational efficiencies, significant pipeline growth, and strategic market expansion initiatives provide a moderately positive outlook for future performance, tempered by ongoing capital needs and current liquidity constraints.

Positives

• Gross profit margin remained strong at approximately 55%, underscoring operational efficiency and technology value.
• International revenue increased to 29% of total revenue in 2025, up from 21% in 2024, indicating successful global market penetration.
• Total operating expenses were reduced by approximately 10% in 2025, demonstrating active cost management.
• Operating loss and net loss both improved year-over-year.
• Sales backlog grew to approximately $1.8 million during 2025, providing improved visibility into near-term revenue conversion.
• Secured significant new customer wins, including selection by NASA for a biosecurity operation, global CDMOs, leaders in eye health, and prestigious university research groups.
• SteraMist was named Disinfection and Decontamination Products Company of the Year 2025 by MedTech Outlook, reflecting market confidence.
• A landmark USDA study confirmed Binary Ionization Technology (BIT) efficacy against deformed wing virus (DWV) for agricultural biosecurity in honeybees.
• Strategic OEM partnerships with ESCO, Steelco, PBSC, Nuaire, and Getinge are driving platform growth and broader distribution.
• Entering the first quarter of 2026 with strong operational momentum, expanding recurring sales, and a growing customer base, with Q1 2026 revenue expected to beat Q1 2025.
• The total opportunity book for integration projects is $16 million, and the entire SteraMist iHP opportunity book is currently at $20 million, representing the strongest pipeline ever.

Negatives

• Net sales decreased to $5,636,000 in 2025 from $7,739,000 in 2024, primarily driven by customers deferring capital expenditure projects due to an uncertain economic environment.
• The company incurred a net loss of $3.7 million in 2025 and used $1.2 million of cash in operating activities.
• Cash and cash equivalents were low at $88,000 as of December 31, 2025.
• The accumulated deficit reached $58.1 million as of December 31, 2025.
• Certain CES project conversions were delayed during 2025 by a tariff-driven slowdown in U.S. pharmaceutical facility capital decisions.

Risks

• Customer deferrals of capital expenditure projects due to uncertain economic environments, including tariffs and the Middle East crisis, may continue to impact sales.
• Liquidity plan relies on the conversion of the sales pipeline, which represents potential future revenue and not committed orders or guarantees of future performance.
• Ability to acquire new customers and expand sales.
• Ability to maintain and manage growth and generate sales.
• Reliance on a single or a few products (BIT platform/SteraMist) for a majority of revenues.
• General business and economic conditions.
• Other risks as described in SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Future Outlook

The company is focused on expanding its presence in the global pharmaceutical manufacturing sector by deepening OEM relationships and supporting customers with integrated, validated decontamination solutions. It plans to partner with new global contract development and manufacturing organizations, whose market size is expanding from $136 billion in 2024 to approximately $191 billion by 2029. The company also sees continued opportunities to penetrate the food safety market, projected to grow from $28 million in 2025 to $31 million in 2026, driven by foodborne illness prevention and stricter regulatory compliance. Additionally, TOMI targets the $5.29 billion medical device sterilization market and emerging markets such as biofuel and honeybee protection. The company expects strong operational momentum in Q1 2026, anticipating revenue to exceed Q1 2025, and boasts a robust opportunity pipeline totaling $16 million for integration projects and $20 million for SteraMist iHP.

Management Comments

• "As we enter 2026, our focus remains on growth and profitability."
• "We plan to continue expanding our presence in the global pharmaceutical manufacturing sector by deepening OEM relationships and supporting customers with integrated, validated decontamination solutions, while partnering with new global contract development and manufacturing organizations whose market size is expanding from $136 billion in 2024 to approximately $191 billion by 2029."
• "In addition, we see continued opportunities to penetrate the food safety market that has a value of $28 million in 2025 and is projected to grow to $31 million in 2026, which is being driven by the rise of foodborne illness prevention initiatives, stricter regulatory compliance, and increasing consumer demand for high-quality, contamination-free food."
• "The global $5.29 billion medical device sterilization market is at our fingertips."
• "Additionally, two very exciting new markets for our future is the biofuel market, which seems to be very favorable for renewables as we focus on domestic energy security, as there are new renewable fuel standards finalized just recently by the EPA, and protecting the worlds pollinators, the honeybees, by leveraging both regulatory developments and growing customer interest in non-toxic, residue-free disinfection technologies."
• "Across all markets, we remain focused on building on our leadership position, improving operational efficiency, and advancing TOMI in a manner that supports long-term value creation."
• "We are just in the process of closing the first quarter of 2026, beating first quarter 2025 revenue. The pipeline that we have is the strongest weve ever had."

Industry Context

StockSavvy.ai notes that TOMI's strategic focus aligns with broader industry trends in biosecurity, clean manufacturing, and the expanding Contract Development and Manufacturing Organization (CDMO) market, which is projected to grow from $136 billion in 2024 to $191 billion by 2029. The emphasis on food safety also capitalizes on increasing regulatory compliance and consumer demand, with the market expected to grow from $28 million in 2025 to $31 million in 2026. The company's exploration of the $5.29 billion medical device sterilization market and emerging areas like biofuel and honeybee protection demonstrates an effort to diversify and capture growth in high-value, regulated sectors, positioning itself within critical global health and environmental initiatives.

Stakeholder Impact

• Shareholders face potential for dilution from future capital raises (ELOC, S-3 shelf) but could benefit from long-term value creation through strategic growth initiatives and pipeline conversion.
• Customers will continue to benefit from the company's decontamination and service solutions, with ongoing product innovation and expanded applications.
• Employees may see opportunities for new hires or expanded roles as the company plans to strengthen its corporate team to support growth.
• Creditors may see reduced risk if the company successfully evaluates options to reduce outstanding convertible note obligations, potentially through equity conversion or ELOC proceeds.

Next Steps

• Expand recurring service contracts with key customers and explore new product lines and/or service offerings to generate a steady income stream.
• Drive year-on-year recurring revenue growth by increasing SteraMist solution sales.
• Continue to grow international presence utilizing targeted marketing campaigns and referral business.
• Pursue additional government and institutional partnerships.
• Strengthen balance sheet flexibility through disciplined financial management.
• Strengthen corporate team to support growth.
• Hold a conference call on March 31, 2026, to discuss full year 2025 results.

Key Dates

Recommendation

While the company reported a significant decline in net sales and continued losses for 2025, the improvement in operating and net loss, coupled with strong gross margins and a substantial future opportunity pipeline, suggests potential for recovery. The strategic initiatives for global expansion, new market penetration, and operational efficiencies are positive indicators. However, the low cash balance and ongoing need for capital, as evidenced by the ELOC and plans for further financing, introduce a degree of risk. For existing investors, holding the stock to observe the conversion of the pipeline and the execution of growth strategies seems prudent, given the mixed signals and the forward-looking optimism.

Keywords

Disinfection, Decontamination, Biosecurity, SteraMist, Binary Ionization Technology, iHP, Life Sciences, Healthcare, Food Safety, Pharmaceutical, CDMO, NASA, USDA, Environmental Solutions, Infection Prevention, Biopharmaceutical, Cell and Gene Therapy, Medical Device Sterilization, Biofuel, Honeybee Protection